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804Adult Human Mesenchymal Stem Cells Added to
Corticosteroid Therapy for the Treatment of Acute
Graft-versus-Host Disease
Partow Kebriaei,1 Luis Isola,2 Erkut Bahceci,3 Kent Holland,4 Scott Rowley,5 Joseph McGuirk,6
Marcel Devetten,7 Jan Jansen,8 Roger Herzig,9 Michael Schuster,10 Rod Monroy,11
Joseph Uberti12The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them a rationale agent
to investigate for graft-versus-host disease (GVHD). Human MSCs were used to treat de novo acute GVHD
(aGVHD). Patients with grades II-IV GVHD were randomized to receive 2 treatments of human MSCs
(Prochymal) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids. Patients re-
ceivedGVHD prophylaxis with tacrolimus, cyclosporine, (CsA) ormycophenolate mofetil (MMF). Study end-
points included safety of Prochymal administration, induction of response to Prochymal, and overall response
of aGVHD by day 28, and long-term safety. Thirty-two patients were enrolled, with 31 evaluable: 21 males, 10
females; median age 52 years (range: 34-67). Twenty-one patients had grade II, 8 had grade III, and 3 had grade
IV aGVHD. Ninety-four percent of patients had an initial response to Prochymal (77% complete response
[CR] and 16% partial response [PR]). No infusional toxicities or ectopic tissue formations were reported.
There was no difference with respect to safety or efficacy between the low and high Prochymal dose. In
conclusion, Prochymal can be infused safely into patients with aGVHD and induces response in a high
proportion of GVHD patients.
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Acute graft-versus-host disease (aGVHD) is a sig-
nificant cause of morbidity and mortality following
allogeneic hematopoietic stem cell transplantation
(HSCT). Depending on the intensity of the condition-
ing regimen, the extent of human leukocyte antigen
(HLA)match, age of the recipient, and stage of the pri-
mary disease, the incidence of aGVHD varies from
20% to 70% [1-5]. Initial treatment with corticoste-
roids remains the standard for aGVHD [6]. However,
even with prompt initiation, steroid therapy is subop-
timal. Two large retrospective studies on the use of
steroids as the primary treatment of aGVHD reported
sustained complete response (CR) rates of only 18%
and 35% [7,8]. Furthermore, in a more recent compar-
ative study, the CR rate for patients treated with
steroids alone was 33% [9]. A recent report suggests
that the addition of mycophenolate mofetil (MMF)
to steroid therapy may improve outcomes in the initial
treatment of GVHD, with a 60%CR rate noted at day
28 [10]. However, other attempts to intensify the im-
munosuppressive therapy as part of the initial treat-
ment of GVHD, either with higher doses of steroids
Biol Blood Marrow Transplant 15:804-811, 2009 805Adult Human Mesenchymal Stem Cells for Treatment of aGVHD[11] or by adding antithymocyte globulin (ATG) [12]
or daclizumab [13], have not improved response rates,
and raise additional safety concerns. Specifically, the
addition of daclizumab to corticosteroid therapy
yielded significantly worse survival because of in-
creased disease relapse and GVHD-related mortality
compared to corticosteroid use alone [13]. At present,
GVHD response rates to steroids are inadequate, and
patients who do not respond to steroid therapy have
a poor prognosis, and 1-year survival rates range
from 10% to 30% [6]. Therefore, it is clear that new
therapeutic agents that are both safe and effective are
needed for the management of aGVHD.
The in vivo and in vitro properties of mesenchymal
stem cells (MSCs), or multipotent mesenchymal stro-
mal cells as defined in the International Society forCel-
lular Therapy position statement [14,15] gives rise to
their potential use in a broad range of inflammatory
and immune-mediated conditions such as GVHD
and Crohn’s disease. Bone marrow-derived MSCs are
a population of undifferentiated pluripotent stem cells
that modulate immune and inflammatory response,
and facilitate repair of connective tissues [16,17].
MSCs have been shown to inhibit the proliferation of
T cells induced by a variety of stimuli [18-20] and
downregulate levels of inflammatory cytokines such
as tumor necrosis factor (TNF)-a and interferon
(IFN)-g [21]. LeBlanc et al. [22] reported the first
case of successful treatment of severe refractory
aGVHD using ex vivo expanded haploidentical human
MSCs. In a subsequent report, these investigators dem-
onstrated a positive therapeutic effect with allogeneic
MSCs in patients experiencing steroid refractory
aGVHD with no significant adverse events attributed
to the cells [23]. Thus, the clinical and experimental
data support the concept of MSCs as therapeutically
tolerated cells without the need for donor-recipient
matching.
Based upon early results ofMSCs for the treatment
of steroid refractory GVHD and an encouraging safety
profile, an open-labeled phase II study was conducted
to determine whether the addition of a preparation of
unrelated, culture-expanded humanMSCs formulated
for intravenous delivery (Prochymal, Osiris Thera-
peutics, Inc., Columbia, MD), to initial corticosteroid
therapy for aGVHDwould improve patient outcomes.PATIENTS AND METHODS
Study Design
The study was a randomized, multicenter, phase II
trial evaluating 2 different dose levels of Prochymal
used in combination with standard corticosteroid ther-
apy for the treatment of aGVHD. The study was ap-
proved by the institutional review board (IRB) of
each of the 16 participating institutions. All patientswere required to give written informed consent before
enrollment in accordance with the Declaration of
Helsinki. Two infusions of Prochymal were adminis-
tered with the first given 24 to 48 hours following di-
agnosis of grade II-IV aGVHD. The second infusion
was given 3 days following the first treatment. Patients
were randomized with equal probability of receiving
either high-dose (8  106 MSCs/kg) or low dose
(2 106MSCs/kg) Prochymal. Patients were stratified
for the 2 dose levels between grades II and grades III/
IV aGVHD. Standard steroid therapy consisted of
methylprednisolone 2 mg/kg i.v. or prednisone 2.5
mg/kg orally daily starting on study day 1 (or up to
72 hours prior to Prochymal dosing), and when indi-
cated, tapered as per institutional standard. Prophylac-
tic therapy with either cyclosporine (CsA) or
tacrolimus, and/or MMF was continued at therapeutic
dose levels. Supportive care, including use of prophy-
lactic antibiotics, was as per institution standards.
The primary endpoint of the study was the propor-
tion of patients who achieved a CR of aGVHD by
study day 28. Secondary endpoints included a partial
response (PR), time to best response, the addition of
escalated immunosuppressive therapy, and survival at
study day 90. Safety endpoints included infusional
toxicity, adverse events, formation of ectopic tissue,
and infection. This report presents safety and efficacy
data through study day 90.
Patients between 18 to 70 years of age inclusive with
newly diagnosed grade II-IV aGVHD requiring sys-
temic steroid therapy were eligible for the study. Biopsy
for confirmation of GVHDwas recommended, but not
required. Patients developing aGVHD after receiving
a HSCT from bone marrow, peripheral blood (PBSC),
or cord blood stem cells, regardless of conditioning reg-
imen, were eligible, as were patients developingGVHD
following donor lymphocyte infusion (DLI). Patients
were required to have adequate renal function.
Exclusion criteria included treatment for aGVHD
with$2 mg/kg of methylprednisolone for .72 hours,
and the use of any investigational agent (not approved
by the FDA for marketed use in any indication) within
30 days of randomization. A central randomization was
utilized for randomization between the high- or low-
dose infusions according to the randomization sched-
ule generated by the study statistician using SAS
PROC PLAN. Subjects were randomized with equal
probability to the treatment arms (2 million cells/kg
of Prochymal or 8 million cells/kg of Prochymal)
using a stratified block design. The stratification factor
was aGVHD grade. For the purpose of stratification,
the aGVHD grades were II and III-IV.Study Assessments
The severity of aGVHD was assessed using the
consensus grading scale [24]. Each study site had an
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of aGVHD grade II-IV of the skin, liver, and gastroin-
testinal (GI) tract documenting both the stage of each
organ and overall grade. aGVHD assessments through
day 28 of the study were performed on study days 1, 4,
7, 14, 21, and 28. Assessment of treatment response
was made based on established clinical criteria. A CR
was defined as the absence of symptoms referable to
aGVHD in all organs. A PR was defined as a decrease
by at least 1 GVHD stage in any 1 organ system with-
out deterioration in others. The best response during
the 28-day period of assessments was recorded for final
response to treatment.Therapy
Human MSCs are isolated from an unrelated, un-
matched donor-derived bone marrow aspirate after
donor screening and testing according to FDA re-
quirements for Blood and Tissue-Based Products.
The product lots of Prochymal used in this study
were derived from 6 different donors within 18-30
years of age.
The ex vivo cultured MSC manufacturing process
is a scaled adaptation of the technique described by
Pittenger et al. [16]. The process consists of 2 steps:
step 1, the production of an in-process intermediate
and step 2, production of a unique Prochymal lot.
The complete process consists of a total of 5 cell pas-
sages. All reagents, equipment, and procedures utilized
in the ex vivo culturedMSCmanufacturing process are
according to FDA GMP.
For processing, the bone marrow aspirate un-
dergoes isolation steps to remove hematopoietic
elements, and then from the nucleated bone marrow
cells, humanMSC expansion occurs in culturemedium
supplemented with 10% fetal bovine serum (FBS) that
has undergone extensive screening for safety and
processing effectiveness. The cells grow as symmetric
fibroblastic colonies, resulting in a cell population
positive for surface antigens, CD105 (SH-2), CD 73
(SH-3, SH-4) CD29, CD44, CD71, CD90, CD106,
CD120a, CD124, CD166, and negative for markers
of hematopoietic lineages, CD14, CD34, and CD45.
Ex vivo cultured MSCs have the ability to proliferate
and retain the ability to undergo in vitro differentiation
to osteogenic, adipogenic, and chondrogenic lineages
when clonally expanded.
The cells are formulated in Plasma-LyteA
containing 5% human serum albumin (HSA) and
10% dimethyl sulfoxide (DMSO) and cryopreserved
at a concentration of 6.6  106 MSC/mL. The in-
process intermediate and final lots are tested for poten-
tial viral pathogens, mycoplasma, sterility, endotoxin,
cell identity, purity, potency, and viability before lots
are released for clinical distribution. Specifically, 2
assays to assess the functional properties of MSCs areused to establish potency for each product lot; a quan-
titative assay measures the expression level of TNFR1
on MSCs and a qualitative assay measures the inhibi-
tion of IL2Ra expression on activated T cells by
MSCs. Purity assays were used to detect the residual
level of hematopoietic cells, bovine protein, and por-
cine trypsin. Prochymal lot release testing and strict
acceptance criteria were incorporated to ensure lot-
to-lot consistency of the manufactured product.
For administration, the cells were thawed and
diluted with Plasma-LyteA to achieve the cell con-
centration needed for infusion. The final infusion
product had a final viable cell concentration of 2.5 
106 MSCs/mL. The final viability was at least 70%
viable MSCs, as determined by Trypan blue testing.
After dilution, theDMSO concentration of the infused
product was 3.75%.The total volume administered for
each patient was dependent upon dose cohort and
body weight. Each patient received cells from only 1
donor. Before infusion, patients were premedicated
with hydrocortisone and diphenhydramine. The infu-
sion was administered i.v. at a rate of 4 to 6 mL/min.
Vital signs and oxygen saturation were measured
within 15 minutes prior to the infusion (time 0) and
then at 15 minutes, 30 minutes, and then hourly until
6 hours after the infusion.
All patients received standard-of-care treatment
with corticosteroids, which was initiated at the time
of GVHD diagnosis. When indicated, steroids were
tapered in accordance with institutional standards.
However, it was recommended that a steroid taper
consisting of a minimal taper rate of at least 10% of
the dose per week be used. If at study evaluation day
7 the patient’s aGVHD worsened, the patient was to
be treated with secondary GVHD therapy determined
by the investigator. Patients on secondary GVHD
therapy were monitored for the 28-day period and
evaluated for GVHD response.Statistical Methods
To detect statistical differences between treatment
groups, the categoric variables of patient demograph-
ics were compared with Fisher’s exact test; age was
compared with a 2-sided t-test, and time of onset of
GVHD since bone marrow transplant was compared
with the Kruskal-Wallis test. CR and PR rates between
treatment groups were compared by Fisher’s exact test.
Time to response after MSC treatment was analyzed
by exact logistic regression. CR was examined for con-
tributing effects of certain baseline characteristics (do-
nor relation, organ involvement at screening, and
initial GVHD grade) and P-values were calculated
from the Breslow-Day test. Survival between complete
responders and noncomplete responders was analyzed
using log rank test. All statistical testing was performed
at a significance level of P\ .05.
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Patient Characteristics
Thirty-two patients were enrolled between April
2005 and June 2006. One patient with a history of
GI bleeding and increased diarrhea at randomization
withdrew informed consent on study day 10. There-
fore, data for 31 patients are reported. The patient
characteristics are listed in Table 1. The median age
of the patients was 52 years (range: 34-67 years) with
21 males and 10 females. Fifteen patients were ran-
domized to receive high-dose Prochymal at 8  106
MSC/kg, and 16 received low dose at 2  106
MSCs/kg. The groups were balanced with respect to
age, sex, donor type, preparative regimen, GVHD
prophylaxis, and GVHD severity. Eighteen patients
received HSCT from matched related donors
(MRD), and 13 patients receivedHSCT frommatched
unrelated donors (MUD). Stem cell source for HSCTTable 1. Patient Characteristics
High Dose
(8  106 MSCs/kg)
No. Patients
Low Dose
(2  106 MSCs/kg)
No. Patients
Sex
Male 10 11
Female 5 5
Median Age, years
(range)
49 (34-67) 53 (42-67)
Disease
AML/MDS 8 6
NHL 2 3
CLL 1 3
ALL 3 1
MMF 0 2
MM 1 0
Hodgkin 0 1
Donor
Related 9 10
Unrelated 6 6
GVHD Grade
II 10 11
III 4 3
IV 1 2
Stem cell source
Bone marrow 0 1
PBSC 15 15
Conditioning
Myeloablative 8 7
Reduced intensity 3 5
Nonmyeloablative 2 2
DLI 2 2
Onset of GVHD
Median days (range) 37 (14-121) 31 (18-115)
GVHD prophylaxis
Cyclosporine 3 3
Tacrolimus 4 6
Tacrolimus + MMF
or MTX
6 5
MSC indicates mesenchymal stem cells; GVHD, graft-versus-host dis-
ease; MMF, mycophenolate mofetil; MTX, methotrexate; DLI, donor
leukocyte infusions; NHL, non-Hodgkin lymphoma; PBSC, peripheral
blood stem cells; AML/MDS, acute myelogenous leukemia/myelodys-
plastic syndromes; ALL, acute lymphoblastic leukemia; CLL, chronic
lymphocytic leukemia; MM, multiple myeloma; MF, myelofibrosis.was peripheral blood for all patients except for 1
patient who received bone marrow. Fifteen patients
received myeloablative preparative regimens and 12
received a reduced or nonmyeloablative regimen.
Four patients developed GVHD following DLI.
GVHD events are described in Table 1. The me-
dian day to the development of GVHD was 37 days
(range: 14-121). All patients had biopsy proven
GHVD: 21 had grade II (12 MRD, 9 MUD) 7 grade
III (3 MRD, 4 MUD), and 3 had grade IV aGVHD
(3 MRD). Of the 21 patients with grade II aGVHD,
12 had skin involvement, 6 had GI involvement, and
3 had GI and skin. Of the 10 patients with grade III-
IV aGVHD, 5 had GI, 2 had liver and GI, 2 had skin
and GI, and 1 had grade IV of the skin.
Treatment Response
GVHDresponse according toMSCs dose is shown
in Table 2. Ninety-four percent of patients had an ini-
tial response to Prochymal (29/31), where 24 patients
(77%) had a CR and 5 (16%) had a PR. Of the 24 pa-
tients who achieved a CR, 10 received high-dose
MSCs, and 14 received low-dose MSCs infusions.
Five patients in the high-dose group achieved a PR
and 2 patients in the low-dose group did not respond.
The CR by time showed that 42% of the patients had
a CR at day 7; 52% at day 14 and 77% at day 28. CR
was further examined for contributing effects of donor
relation, GVHD organ involvement and GVHD
grade, and no statistically significant effect was noted
(Table 3). Of the 24 patients who achieved a CR, 19
maintained their response for at least 90 days without
requiring second-line GVHD therapy. Five of the 24
patients who achieved an initial CR required additional
therapy during the first 28 days. Two patients received
second-line therapywith infliximab, 1 onday 6 and 1on
day 10, and both achieved a CR at day 28. Three
patients, who initially achieved a CR, had flares of their
GVHD between days 10 and 12 and required second-
line therapy on days 12, 13, and 15. One of these 3
patients showed an improvement in their GVHD
symptoms after initiating second-line agents.
Five patients experienced a PR. Three of these pa-
tients received second-line therapy for their GVHD.
None responded, and all 3 died of GVHD-related
complications within 90 days of their first treatment.
The remaining 2 patients achieved significantTable 2. Induction of GVHD Response to Treatment
Response Type
High-Dose
(8  106 MSCs/kg)
No. Patients (%)
Low-Dose
(2  106 MSCs/kg)
No. Patients (%)
Total
(N 5 31)
No. Patients (%)
Complete
Response
10 (66.7) 14 ( 87.5) 24 (77.4)
Partial Response 5 (33.3) 0 5 (16.1)
No Response 0 2 (12.5) 2 (6.5)
GVHDindicates graft-versus-host disease;MSCs,mesenchymal stemcells.
Table 3. Summary of Complete Response by Patient Characteristics
High-Dose
8  106 MSCs/kg
No. Pts (%) 90% CI
Low-Dose
2  106 MSCs/kg
No. Pts (%) 90% CI
P value
(BreslowDay test)
Donor matching
Matched unrelated Donor
Complete response 3 (20) 7.8%-41.4% 6 (35) 19.4%-55.2%
No complete response 2 (13) 3.6%-34.3% 2 (12) 3.1%-30.9%
Matched related donor
Complete response 7 (47) 27.7%-66.7% 8 (47) 29.0%-66.0%
No complete response 3 (20) 7.8%-41.4% 1 (6) 0.0%-24.0% .76
Organ involvement
Skin Only
Complete response 3 (20) 7.8%-41.4% 8 (47) 29.0%-66.0%
No complete response 2 (13) 3.6%-34.3% 0 (0) 0.0%-10.5%
Other
Complete response 7 (47) 27.7%-66.7% 6 (35) 19.4%-55.2%
No complete response 3 (20) 7.8%-41.4% 3 (18) 6.7%-37.5% .09
GVHD grade
Grade II
Complete response 9 (60) 39.2%-77.7% 10 (59) 39.3%-75.9%
No complete response 2 (13) 3.6%-34.3% 1 (6) 0.0%-24.0%
Grade III-IV
Complete response 1 (7) 0.0%-26.6% 4 (24) 10.7%-43.6%
No complete response 3 (20 7.8%-41.4% 2 (12) 3.1%-30.9% .61
GVHD indicates graft-versus-host disease; MSCs, mesenchymal stem cells; CI, confidence interval; Pts., patients.
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therapy: 1 patient had stage iii skin aGVHD that im-
proved to stage i by day 7, but had a traumatic fall
and died of intracranial hemorrhage on day 13. The
second patient had stage iv skin aGVHD that im-
proved to stage i, but the patient’s underlying leukemia
relapsed and the patient died on day 24.
Only 2 patients did not show response to therapy
by study day 28. One patient’s GVHD therapy was
not escalated because of concurrent CMV infection.
The second patient was placed on infliximab but
continued to have diarrhea associated with GI
GVHD.
Four patients developed GVHD following DLI; 2
patients received chemotherapy precedingDLI. Three
of the 4 patients achieved a CR with treatment; 1 of
these patients had grade II skin, 1 had grade III GI,
and 1 had grade IV GI and liver involvement. OneTable 4. Summary of Response by Initial Organ System Involved
Organ System
No. Patients Grade Response
Hig
8  1
No
Skin only II CR
N 5 13 PR
III/IV PR
GI only II CR
N 5 11
III/IV CR
PR
NR
Multiorgan II CR
N 5 7
III/IV CR
PR
MSCs, mesenchymal stem cells; CR, complete response; PR, partial response;patient who developed grade III skin GVHD achieved
a PR with treatment.
Response by organ system is shown in Table 4. A
total of 13 patients had only skin involvement and all
13 responded, with 11 achieving a CR (85%). Of the
11 patients with GVHD only in the GI tract, 9 of 11
(82%) responded, and 8 (73%) had a CR. Seven
patients had multiorgan involvement, and all 7 re-
sponded, with 5 patients having CR (71%). Response
by initial GVHD grade is also provided in Table 4.
Additionally, the source of MSCs was evaluated
with regards to impact on response. Twenty-three
of the 32 patients treated received MSCs from 2 dif-
ferent donors, and the remaining patients received
MSCs from 4 different MSC donors. A comparison
of response between the 2 donors who supplied the
majority of patients showed no difference (P 5
.224, Fisher’s exact test). The remaining 4 MSCh-Dose
06 MSCs/kg
. Patients
Low-Dose
2  106 MSCs/kg
No. Patients
Total
No. Patients (%)
3 8 11 (85)
1 0 1 (8)
1 0 1 (8)
3 2 5 (45)
1 2 3 (27)
1 0 1 (9)
0 2 2 (18)
2 1 3 (43)
1 1 2 (29)
2 0 2 (29)
GI, gastrointestinal.
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Survival
Twenty-two patients on the study survived to day
90. Patients who achieved a CR to GVHD therapy
had significantly higher survival rate (P 5 .00008) at
day 90. Out of 24 patients that achieved a CR, 21
(88%) were alive at day 90. Of the 7 patients that did
not achieve a CR, only 1 (14%) was alive at day 90.
Nine patients on the study died amedian of 44 days
(range: 13-63) from the first Prochymal infusion.
Three patients who achieved a CR died; the causes
of death were pneumonia, meningitis, and aspergillus
enteritis. All 5 patients with a PR died. Three died of
progressive GVHD, 1 of underlying disease relapse,
and 1 of a central nervous system (CNS) bleed. Of
the 2 patients who had no response, 1 died of progres-
sive GVHD and 1 survived to day 90.
The effect on survival of adding second-line ther-
apy to treat progressiveGVHDwas examined. Twenty
of 22 patients (91%) did not need second-line therapy
and were alive at day 90. In contrast, 9 patients
required second-line therapy within the first 28 days,
and only 3 (33%) survived to day 90 (P 5 .0011).
Safety
There were a total of 62 infusions of Prochymal
administered to 31 patients. All infusions were well
tolerated with no acute infusional toxicity and no
adverse events associated with Prochymal infusions.
Ectopic tissue was not detected by computed tomogra-
phy (CT) imaging in any patients at study day 28.
Furthermore, continued follow-up with CT scans at
1 and 2 years following MSC infusion on the long-
term study has not shown any evidence for ectopic tis-
sue formation. Twelve grade 3 infections, defined as
per CTC versus 3, were reported: adenovirus (n 5 1),
bacteremia (n 5 4), cytomegalovirus (CMV) viremia
(n5 5), and BK virus-associated cystitis (n5 2). Three
grade 4 infections were reported: pseudomonal pneu-
monia (n 5 1), eneteroccocal meningitis (n 5 1) and
aspergillus enteritis (n 5 1). There was no correlation
between Prochymal dose and toxicity grade. During
the 90-day period, 1 patient with acute lymphoblastic
leukemia (ALL) who underwent a second HSCT had
disease relapse. Two additional patients relapsed dur-
ing the long-term follow-up study: 1 patient had refrac-
tory relapsed ALL and 1 had relapsed Hodgkin disease
(HD), and had received a prior autologous SCT.DISCUSSION
The use ofMSCs is a promising new strategy in the
treatment of aGVHD. MSCs give rise to mesodermal
tissue types including bone, cartilage, tendon, muscle,and fat [25,26], and are capable of modulating immune
response and inflammation [18-21]. MSCs also secrete
factors that stimulate angiogenesis, tissue repair, and
hematopoietic stem cell engraftment [25,27]. One of
the key advantages of MSCs is that histocompatibility
matching has not been required for therapeutic effect
[19]. TheMSCs do not expressHLA class II histocom-
patibility antigens, and furthermore, do not express ac-
cessory molecules, CD40, CD80, and CD86, required
for immune cell activation. An important biologic
property of MSCs is their chemotactic response to in-
flammatory factors generally reserved for the migra-
tion of neutrophils and other immune responsive
cells. This homing property has been demonstrated
in a number of animal models of injury including cere-
bral ischemia [28], total-body irradiation (TBI)
[29,30], and myocardial infarction [31,32]. Once at
the site of injury or inflammation, it has been proposed
that MSCs modulate immune and inflammatory reac-
tions at the microenvironment level and stimulate tis-
sue repair of the affected organs.
This study represents the first prospective trial of
third-party, unmatched MSCs for the treatment of de
novo aGVHD. These results corroborate the reports
of MSCs used in the treatment of steroid refractory
GVHD [22,33]. The results of this study provide
evidence that MSCs can effectively induce a response
in a high percentage of GVHD cases, and when used
in combination with existing therapy, may improve
overall outcome. Seventy-seven percent of patients
had an intial CR following the initiation of steroids
and Prochymal therapy. In themajority of these patients
(19 of 24), the response was maintained for 90 days.
Of particular interest is the low number of patients
that do not respond to treatment. It is hypothesized
that the broad immunomodulatory properties of
MSCs, responsible for the secretion of multiple anti-
inflammatory cytokines, are more effective than
targeted small molecules or biologics for the treatment
of GVHD. In line with previous observations from
individual case studies using Prochymal to treat GI
GVHD [22], a high response rate was observed in
patients with GI GVHD. In this study, 18 patients
had GI GVHD (GI alone or GI with skin or liver), 16
of 18 (89%) responded and 13 (72%) achieved a CR
of theirGI component.Other studies have also demon-
strated that administering third-party MSCs to pa-
tients with steroid refractory aGVHD improved the
clinical symptoms of lower GI tract [22,33]. In a recent
report, data from a multicenter study were presented
summarizing treatment with MSCs for 55 children
and adults with steroid-refractory aGVHD.Overall re-
sponse was 71%, with 55% CR. In corroboration with
our findings, CRpatients had improved overall survival
(OS) at 2 years after HSCT compared to patients with
less than CR, 53% versus 16%, P5 .018 [33]. Further-
more, there was suggestion of a better response rate in
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Similarly, positive clinical responses and improved sur-
vival were recently reported for pediatric patients
treated with MSCs for steroid refractory aGVHD.
Seven of 12 (58%) treated patients achieved CR with
the best responses in patients with GI involvement
(75%). Five (42%) were alive at a median follow-up
time of 229 days [35].
Our study was not designed to assess the optimal
dose and schedule of Prochymal administration. Five
patients who achieved a CR had flares of their
GVHD that required second-line therapy, suggesting
that 2 doses of Prochymal may be insufficient to main-
tain a CR. Le Blanc et al. [33] reported that multiple
infusions were needed for sustained response in more
that half of the patients treated with MSCs for steroid
refractory GVHD. Furthermore, the low dose of Pro-
chymal at 2  106 cells/kg appeared as effective as the
higher dose in inducing a response, consistent with
other MSC GVHD study reports [22,33,35].
Althoughmany studies have shown thatmethods to
prevent GVHD often result in increased relapse rates,
it is unclear if more effective treatment for established
aGVHD will increase relapse. Three patients in our
study relapsed during a follow-up period of 2 years.
All 3 had advanced disease, including 1 with a prior
transplant, and had a high likelihood of relapse. Ning
et al. [28] published a small randomized trial in which
humanMSCs were cotransplanted with hematopoietic
stem cells in efforts to improve engraftment time; there
was no impact on engraftment, but they noted a higher
relapse rate in the group treated with MSCs compared
to the non-MSC group, (6 of 10 versus 3 of 15, respec-
tively). Of interest, the MSC group had a lower inci-
dence of aGVHD and chronic GVHD (cGVHD).
This increase in relapse rate was not noted in an earlier
study by Lazarus et al. [36], in which MSCs were also
cotransplanted with HSC to improve engraftment.
No infusional toxicity was attributable to Prochy-
mal infusions. Furthermore, adverse events and rates
of infection were similar across both Prochymal dose
groups. There were 3 deaths resulting from infection
in the absence of ongoing GVHD. This rate (10%)
is within expectations for this heavily immunosup-
pressed population.
In conclusion,MSCs represent a newpotential ther-
apeutic option in the treatment of GVHD. Third-party
human MSCs can be infused safely into patients with
aGVHD and may improve clinical symptoms. A larger,
blinded, placebo-controlled trial with Prochymal is
warranted to fully investigate these encouraging results.ACKNOWLEDGMENTS
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